Overview

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants

Status:
Not yet recruiting

Trial end date:
2041-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Phase:

Phase 3

Details

Lead Sponsor:

European Myeloma Network

Collaborator:

Janssen Research & Development, LLC

Treatments:

Bortezomib
Cyclophosphamide
Daratumumab
Dexamethasone
Fludarabine
Lenalidomide